Monovalent, bivalent and single-chain fold-back diabody anti-human CCR4 DT-based immunotoxins were successfully produced in yeast and demonstrated to be effective and specific in a human CCR4+ tumour bearing NSG mouse model [67]. This evidence concerns the gene CCR4 and neoplasm.